Top Markets
Coin of the day
Rapport Therapeutics, Inc. Common Stock Rapport Therapeutics, Inc. Common Stock

Rapport Therapeutics, Inc. Common Stock

RAPP
Peringkat dalam Saham #5670
Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical... Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder. The company's pipeline further includes RAP-199, another molecule targeting TARPy8, which boasts distinct chemical and pharmacokinetic profiles. Moreover, Rapport is advancing several nicotinic acetylcholine receptor (nAChR) programs, such as an a6 nAChR therapy for chronic pain and an a9a10 nAChR treatment intended for hearing impairments. Formed in 2022 under the initial name Precision Neuroscience NewCo, Inc., the company adopted its current identity as Rapport Therapeutics, Inc. in October 2022, and its operations are based in Boston, Massachusetts.
Harga Saham
$52.78
Terakhir disinkronkan: 2026-08-26
Kapitalisasi Pasar
$2.52B
Perubahan (1 hari)
3.14%
Perubahan (1 tahun)
252.56%
Negara
US
Perdagangan Rapport Therapeutics, Inc. Common Stock (RAPP)

Kategori

Laba untuk Rapport Therapeutics, Inc. Common Stock (RAPP)
Laba pada 2026 TTM: 0
Menurut laporan keuangan terbaru dari Rapport Therapeutics, Inc. Common Stock, laba saat ini perusahaan adalah 0. Pada tahun 2026, perusahaan memperoleh laba sebesar 0, sama dengan laba tahun 2026 sebesar 0. Laba yang ditampilkan di halaman ini adalah laba sebelum bunga dan pajak, atau disebut juga EBIT.
Riwayat laba untuk Rapport Therapeutics, Inc. Common Stock dari 2026 hingga 2026
Laba pada akhir setiap tahun
Tahun Laba Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Laba untuk perusahaan serupa atau pesaing
Perusahaan Laba Perbedaan Laba Negara
$5.27B -
US
$1.95B -
NL
$-3.09B -
US
$-4.02B -
AU
- -
CH